| 摘要 |
<p>An antidementia drug containing a BEC1 potassium channel inhibitor as the active ingredient. It is proved that the BEC1 potassium channel inhibitor has an effect of ameliorating learning disability and is useful as a preventive or a remedy for diseases in which the BEC1 potassium channel seemingly participates, preferably dementia. More specifically, it is confirmed that the BEC1 potassium channel inhibitor exhibits an effect of ameliorating learning disability in an in vivo test. It is also found out that a compound having 2,4,6-trimaino-1,3,5-triazine has an effect of inhibiting the BEC1 potassium channel.</p> |
